{
    "root": "e54d008a-9b47-42fa-a8c1-23dc72527132",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Naproxen",
    "value": "20250314",
    "ingredients": [
        {
            "name": "NAPROXEN",
            "code": "57Y76R9ATQ"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        }
    ],
    "indications": "naproxen tablets indicated : relief signs symptoms : rheumatoid arthritis osteoarthritis ankylosing spondylitis polyarticular juvenile idiopathic arthritis tendonitis bursitis acute gout management : pain primary dysmenorrhea",
    "contraindications": "lowest effective shortest duration consistent individual patient treatment goals . ( 2.1 ) r h e u toid arthritis , osteoarthritis , ankylosing spondylitis naproxen tablets 250 mg 375 mg 500 mg twice daily twice daily twice daily dose may adjusted depending response patient . patients tolerate lower doses well , dose may increased naproxen 1,500 mg/day 6 months . polyarticular juvenile idiopathic arthritis naproxen tablets may allow flexible dose titration needed pediatric patients polyarticular juvenile idiopathic arthritis . liquid formulation may appropriate . recommended total daily dose naproxen approximately 10 mg/kg given 2 divided doses . dosing naproxen tablets appropriate children weighing less 50 kilograms . c u te gout recommended starting dose 750 mg naproxen tablets followed 250 mg every 8 hours attack subsided .",
    "warningsAndPrecautions": "naproxen tablets usp , 250 mg , supplied white , round , biconvex tablets , debossed \u201c ip 188 \u201d obverse \u201c 250 \u201d reverse . available follows : bottles 100 : ndc 53746-188-01 bottles 500 : ndc 53746-188-05 bottles 1000 : ndc 53746-188-10 naproxen tablets usp , 375 mg , supplied white , capsule-shaped , biconvex tablets , debossed \u201c ip 189 \u201d obverse \u201c 375 \u201d reverse . available follows : bottles 100 : ndc 53746-189-01 bottles 500 : ndc 53746-189-05 bottles 1000 : ndc 53746-189-10 naproxen tablets usp , 500 mg , supplied white , capsule-shaped , biconvex tablets , debossed \u201c ip 190 \u201d obverse \u201c 500 \u201d reverse . available follows : bottles 100 : ndc 53746-190-01 bottles 500 : ndc 53746-190-05 bottles 1000 : ndc 53746-190-10 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . dispense well-closed , light-resistant containers defined usp .",
    "adverseReactions": "naproxen tablets contraindicated following patients : known hypersensitivity ( e.g . , anaphylactic serious skin ) naproxen components product [ ( 5.7 , 5.9 ) ] history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids reported patients [ ( 5.7 , 5.8 ) ] setting coronary artery bypass graft ( cabg ) surgery [ ( 5.1 ) ]",
    "indications_original": "Naproxen tablets are indicated for:\n                  The relief of the signs and symptoms of:\n                  \n                     rheumatoid arthritis\n                     osteoarthritis\n                     ankylosing spondylitis\n                     Polyarticular Juvenile Idiopathic Arthritis\n                     tendonitis\n                     bursitis\n                     acute gout\n                  \n                  The management of:\n                  \n                     pain\n                     primary dysmenorrhea",
    "contraindications_original": "Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. ( 2.1 ) R h e u m a toid Arthritis, Osteoarthritis, and Ankylosing Spondylitis Naproxen tablets 250 mg 375 mg 500 mg twice daily twice daily twice daily The dose may be adjusted up or down depending on the clinical response of the patient. In patients who tolerate lower doses well, the dose may be increased to naproxen 1,500 mg/day for up to 6 months. Polyarticular Juvenile Idiopathic Arthritis Naproxen tablets may not allow for the flexible dose titration needed in pediatric patients with polyarticular juvenile idiopathic arthritis. A liquid formulation may be more appropriate. Recommended total daily dose of naproxen is approximately 10 mg/kg given in 2 divided doses. Dosing with naproxen tablets is not appropriate for children weighing less than 50 kilograms. A c u te Gout Recommended starting dose 750 mg of naproxen tablets followed by 250 mg every 8 hours until the attack has subsided.",
    "warningsAndPrecautions_original": "Naproxen Tablets USP, 250 mg, are supplied as white, round, biconvex tablets, debossed with \u201cIP 188\u201d on obverse and \u201c250\u201d on the reverse. They are available as follows:\n                  Bottles of 100:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 53746-188-01\n                  Bottles of 500:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 53746-188-05\n                  Bottles of 1000:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 53746-188-10\n                  Naproxen Tablets USP, 375 mg, are supplied as white, capsule-shaped, biconvex tablets, debossed with \u201cIP 189\u201d on obverse and \u201c375\u201d on the reverse. They are available as follows:\n                  Bottles of 100: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 53746-189-01\n                  Bottles of 500: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 53746-189-05\n                  Bottles of 1000:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 NDC 53746-189-10\n                  Naproxen Tablets USP, 500 mg, are supplied as white, capsule-shaped, biconvex tablets, debossed with \u201cIP 190\u201d on obverse and \u201c500\u201d on the reverse. They are available as follows:\n                  Bottles of 100:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 53746-190-01\n                  Bottles of 500: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 53746-190-05\n                  Bottles of 1000:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 53746-190-10\n                   Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted between 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature]. Dispense in well-closed, light-resistant containers as defined in the USP.",
    "adverseReactions_original": "Naproxen tablets are contraindicated in the following patients:\n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [see Warnings and Precautions (5.7, 5.9)]\n                     \n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients [see Warnings and Precautions (5.7, 5.8)]\n                     \n                     In the setting of coronary artery bypass graft (CABG) surgery [see Warnings and Precautions (5.1)]"
}